Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study.

ABSTRACT:

Background

The use of opioid analgesics for patients with chronic nonmalignant pain is becoming more widely accepted, and long-acting formulations are an important treatment option.

Aim

To assess conversion to extended-release OROS hydromorphone from previous stable opioid agonist therapy in patients with chronic nonmalignant pain of moderate-to-severe intensity.

Methods

In this open-label multicentre trial, patients were stabilised on their previous opioid therapy before being switched to OROS hydromorphone at a ratio of 5 : 1 (morphine sulphate equivalent to hydromorphone hydrochloride). The OROS hydromorphone dose was titrated over 3-16 days to achieve effective analgesia, and maintenance treatment continued for 14 days.

Results

Study medication was received

SUBMITTER: Wallace M 

PROVIDER: S-EPMC2040191 | biostudies-literature | 2007 Oct

REPOSITORIES: biostudies-literature